Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Oct;5(10):1811-1814.
doi: 10.1016/j.ekir.2020.06.039. Epub 2020 Jul 12.

Hydroxychloroquine-Associated Hypoglycemia in Hemodialysis Patients With COVID-19

Ahmet Burak Dirim  1 , Erol Demir  1 , Seda Safak  1 , Nurana Garayeva  1 , Ali Riza Ucar  1 , Ozgur Akin Oto  1 , Halil Yazici  1 , Alpay Medetalibeyoglu  2 , Murat Kose  2 , Figen Esen  3 , Serap Simsek Yavuz  4 , Aydin Turkmen  1
Affiliations
Case Reports

Hydroxychloroquine-Associated Hypoglycemia in Hemodialysis Patients With COVID-19

Ahmet Burak Dirim et al. Kidney Int Rep. 2020 Oct.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
The course of morning fasting blood glucose levels of 3 hypoglycemic patients during coronavirus disease 2019 (COVID-19) treatment. D10W, 10% dextrose solution; HCQ, hydroxychloroquine.
See this image and copyright information in PMC

References

    1. Durcan L., Clarke W.A., Magder L.S. Hydroxychloroquine Blood Levels in SLE: Clarifying dosing controversies and improving adherence. J Rheumatol. 2015;42:2092–2097. - PMC - PubMed
    1. Schrezenmeie E., Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16:155–166. - PubMed
    1. Liu J., Cao R., Xu M. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. - PMC - PubMed
    1. Tett S.E., Cutler D.J., Ray A.O. A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol. 1998;26:303–313. - PMC - PubMed
    1. Izzeddine H., Jhaveri K.D., Perazella M.A. COVID-19 therapeutic options for patients with kidney disease. Kidney Int. 2020;97:1297–1298. - PMC - PubMed

Publication types

LinkOut - more resources